Penetration testing for pacemakers, ICDs, insertable cardiac monitors, and home-monitor backhaul. Pairing, telemetry, and field-update path testing.
Last reviewed March 2026 · Reviewed against the FDA Feb 3, 2026 final premarket cybersecurity guidance.
Cardiovascular devices - pacemakers, ICDs, CRT-Ds, insertable cardiac monitors, home-monitor transmitters - have the longest deployed lifetimes and the most public history of cybersecurity recalls in the industry. Our pen testing is built around what FDA's CDRH cardiovascular reviewers and CISA have actually called out: programmer-to-device pairing, RF telemetry confidentiality and integrity, home-monitor backhaul, and the long tail of postmarket update channels.
We exercise the in-clinic programmer interface (MedRadio RF on most current devices, BLE on newer patient-side links, inductive on older programmers and wake-up handshakes) for mutual authentication, session-key freshness, and replay resistance. We model the home-monitor as an untrusted bridge: assuming a compromised transmitter, can it issue programming commands or just relay telemetry? Most fail this test on first pass because the device trusts any session that completes pairing. We also test the cellular and Wi-Fi backhaul out of the home monitor - TLS pinning, certificate validation, attestation of the monitor identity to the cloud - and the cloud-side APIs that clinicians use for remote follow-up. Implant-side, we evaluate the firmware update path: signed update enforcement, rollback protection, and behavior under interrupted update (because explant is not an option). The deliverable is a report your design team can act on AND a set of risk-control test evidence your regulatory team can drop into the SPDF and PMA cybersecurity sections.
The cardiovascular system, from the outermost cloud and clinician surfaces down to the device itself. Highlighted layers are exercised by this medical device penetration testing.
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Four phases, fixed fee, scoped to cardiovascular architecture from kickoff onward.
Architecture review, attack-surface walkthrough, and threat-model alignment with your team. Written scope in 24 hours.
Every STRIDE entry in your threat model is matched to a planned test case so reviewers see one-to-one coverage.
Device, cloud, mobile, BLE/RF, and OTA channels exercised in parallel by senior engineers - not a single web-app scan.
eSTAR-format report with findings, CVSS, remediation, and retests until every finding is closed.
The patterns we hit in this segment, this service, again and again.
Captured pairing exchange replays successfully against the same implant for the duration of the battery life. Mutual auth is present in spec but not in firmware.
Once paired, the home monitor can issue command opcodes that should be programmer-only. The threat model assumed home monitors were read-only; the firmware did not enforce it.
Home-monitor MQTT/HTTPS endpoints validate CA chain but not specific cert. A network-position attacker with a CA-trusted cert can MITM telemetry and acks.
Predictable IDOR on /devices/{serial}/episodes returns ECG strips for any account when caller is authenticated but not authorized. Classic broken-object-level authorization.
Field-service update tool from a previous generation still accepts older signed bundles. Attacker with physical/programmer access can downgrade to a known-vulnerable build.
Recalls, CISA ICS-MA advisories, and disclosed research that shape what reviewers ask about in this segment - and what our scope is built to cover.
Software-update integrity gap allowed a network-positioned attacker to alter programmer software, indirectly affecting implant programming. FDA-issued safety communication followed.
OTA firmware update issued to address authentication weaknesses on the home transmitter that could permit unauthorized programming commands to implants.
Conexus RF protocol lacked encryption and authentication, allowing nearby attackers to read or modify implant communications. Drove industry-wide expectations on telemetry confidentiality and integrity.
"Blue Goat Cyber helped us navigate our first end-to-end cybersecurity testing for our wearable medical device. Their communication was excellent, their timeline exceeded expectations, and their report helped us achieve FDA clearance without any additional questions. It was a truly seamless experience."
The same deliverables the parent Medical Device Penetration Testing service ships with - tuned to your cardiovascular architecture.
Reviewer-format documents ready to drop straight into the cybersecurity attachments of your submission - no reformatting on your side.
The Cardiovascular baseline, plus the call-outs that matter for medical device penetration testing in this segment.
Cardiac device reviewers expect this referenced in your security risk-control evidence - particularly for programmer↔device interfaces.
10-15 year fleets demand SBOM monitoring + a documented coordinated vulnerability disclosure program. Pen test scope must include the postmarket update path, not just the as-shipped device.
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
The questions buyers in this segment actually ask before scoping a medical device penetration testing engagement.
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
The most common high- and critical-severity findings we surface in medical device penetration tests, what each one looks like in the field, and how to fix it before your FDA submission.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
What is MedTech, and how does it differ from a medical device or life sciences? Clear definitions, from scalpels and sutures to connected cyber devices.
Ransomware and medical devices: how attacks reach connected devices, what the FDA's 2026 premarket guidance expects, and the design controls that limit harm.
What is a cyber device under FDA Section 524B? The three-part legal test, how the FDA reads internet connection, and a quick check for your own device.
Teams in this segment commonly bundle these alongside medical device penetration testing.
A 30-minute call with a senior engineer who has done this in cardiovascular before - not a sales rep.
